-
Sona Announces Ethics Committee Approval For Melanoma Clinical Trial
-
Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
-
Sona Successfully Completes FDA-Required Toxicity Study
-
Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
-
BioVaxys and Sona Nanotech Enter Research Collaboration
-
Sona Nanotech Announces Annual Options Grants
-
Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model
-
Sona Nanotech Inc. CEO David Regan to Present at the Investor Summit Virtual on March 11
-
Sona Nanotech's Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference
-
Sona Nanotech's THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal
-
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study
-
Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update
-
Sona Nanotech Issued Patent and Appoints New Board Member
-
Sona Nanotech Grants Options
-
Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds
-
Sona Nanotech Closes Private Placement Financing to Raise $1,500,000 in Gross Proceeds and Announces Additional Financing
-
Sona Nanotech to Arrange Private Placement Financing
-
Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study
-
Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer
Top News
